Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.

Hdl Handle:
http://hdl.handle.net/10147/313301
Title:
Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.
Authors:
McDermott, Edel; Murphy, Seamus; Keegan, Denise; O'Donoghue, Diarmuid; Mulcahy, Hugh; Doherty, Glen
Affiliation:
Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. edelmcdermott@physicians.ie
Citation:
Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. 2013, 7 (2):150-3 J Crohns Colitis
Journal:
Journal of Crohn's & colitis
Issue Date:
Mar-2013
URI:
http://hdl.handle.net/10147/313301
DOI:
10.1016/j.crohns.2012.03.016
PubMed ID:
22520592
Abstract:
Adalimumab is a recombinant human IgG1 monoclonal antibody to TNF-alpha. There are limited data with regard to its efficacy in ulcerative colitis. We report experience of adalimumab in ulcerative colitis in a single centre with a focus on the ability of this agent to maintain response and avoid colectomy in the medium to long-term.
Item Type:
Article
Language:
en
MeSH:
Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Colectomy; Colitis, Ulcerative; Female; Follow-Up Studies; Humans; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Failure
ISSN:
1876-4479

Full metadata record

DC FieldValue Language
dc.contributor.authorMcDermott, Edelen_GB
dc.contributor.authorMurphy, Seamusen_GB
dc.contributor.authorKeegan, Deniseen_GB
dc.contributor.authorO'Donoghue, Diarmuiden_GB
dc.contributor.authorMulcahy, Hughen_GB
dc.contributor.authorDoherty, Glenen_GB
dc.date.accessioned2014-02-24T11:42:05Z-
dc.date.available2014-02-24T11:42:05Z-
dc.date.issued2013-03-
dc.identifier.citationEfficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. 2013, 7 (2):150-3 J Crohns Colitisen_GB
dc.identifier.issn1876-4479-
dc.identifier.pmid22520592-
dc.identifier.doi10.1016/j.crohns.2012.03.016-
dc.identifier.urihttp://hdl.handle.net/10147/313301-
dc.description.abstractAdalimumab is a recombinant human IgG1 monoclonal antibody to TNF-alpha. There are limited data with regard to its efficacy in ulcerative colitis. We report experience of adalimumab in ulcerative colitis in a single centre with a focus on the ability of this agent to maintain response and avoid colectomy in the medium to long-term.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of Crohn's & colitisen_GB
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal-
dc.subject.meshAntibodies, Monoclonal, Humanized-
dc.subject.meshColectomy-
dc.subject.meshColitis, Ulcerative-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshMaintenance Chemotherapy-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRetrospective Studies-
dc.subject.meshTime Factors-
dc.subject.meshTreatment Failure-
dc.titleEfficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.en_GB
dc.typeArticleen
dc.contributor.departmentCentre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. edelmcdermott@physicians.ieen_GB
dc.identifier.journalJournal of Crohn's & colitisen_GB
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.